Abstract

The tau protein is central to the etiology of several neurodegenerative diseases, including Alzheimer's disease, a subset of frontotemporal dementias, progressive supranuclear palsy and dementia following traumatic brain injury, yet the proteins it interacts with have not been studied using a systematic discovery approach. Here we employed mild in vivo crosslinking, isobaric labeling, and tandem mass spectrometry to characterize molecular interactions of human tau in a neuroblastoma cell model. The study revealed a robust association of tau with the ribonucleoproteome, including major protein complexes involved in RNA processing and translation, and documented binding of tau to several heat shock proteins, the proteasome and microtubule-associated proteins. Follow-up experiments determined the relative contribution of cellular RNA to the tau interactome and mapped interactions to N- or C-terminal tau domains. We further document that expression of P301L mutant tau disrupts interactions of the C-terminal half of tau with heat shock proteins and the proteasome. The data are consistent with a model whereby a higher propensity of P301L mutant tau to aggregate may reflect a perturbation of its chaperone-assisted stabilization and proteasome-dependent degradation. Finally, using a global proteomics approach, we show that heterologous expression of a tau construct that lacks the C-terminal domain, including the microtubule binding domain, does not cause a discernible shift of the proteome except for a significant direct correlation of steady-state levels of tau and cystatin B.

Highlights

  • The tau protein is a member of the family of microtubuleassociated proteins (MAPs)1 that in humans is coded by the MAPT gene on chromosome 17q21.31 [1]

  • Similar tau aggregates have since been described in other, less common dementias, including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick’s disease and dementia pugilistica, a form of dementia observed in athletes who had been exposed to repeated traumatic brain injury [5]

  • The enhanced green fluorescent protein (EGFP) fusion was selected on the basis of prior results by others that documented that the C-terminal addition of this tag to the tau protein neither interferes with its binding to microtubules nor with the manifestation of tau-dependent toxicity in cells exposed to amyloid ␤ [36]

Read more

Summary

Introduction

The tau protein is a member of the family of microtubuleassociated proteins (MAPs) that in humans is coded by the MAPT gene on chromosome 17q21.31 [1]. The protein has long been known to exhibit some remarkable biochemical characteristics, including an ability to withstand harsh acid and heat treatments that would cause a majority of other proteins to precipitate [2, 14]. These characteristics have been attributed to tau being natively unfolded and possessing a highly dynamic character [15]. We narrowed down the binding preference of individual binders to N-

Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.